LOGIN  |  REGISTER
Astria Therapeutics
Assertio

Amwell to report first quarter 2025 operating results

April 17, 2025 | Last Trade: US$8.48 0.16 -1.85

BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leader in digital care, will report first quarter 2025 operating results after stock market trading hours on Thursday, May 1 2025.

Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update.

The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at investors.amwell.com for approximately 90 days.

About Amwell  

Amwell offers payers and health systems a single, comprehensive, technology-enabled care platform. We use technology to provide patients with better access to more convenient, affordable and effective care. The Amwell platform includes software and services that power many clinical programs from Amwell and our growing number of partners. Our platform allows patients to experience unified, personalized and simple access to diversified clinical programs across the care continuum. As more people seek care online and more clinical programs become available, we offer integrated, future-ready, consistent solutions. The Amwell platform is proven, operating at a large scale, enabling care for millions of patients and their sponsors while delivering dependable outcomes. For almost two decades, Amwell has proudly served some of the largest and most sophisticated healthcare organizations in the U.S. and worldwide. For more information, visit business.amwell.com or LinkedIn.

©2025 American Well Corporation. All rights reserved. Amwell®, SilverCloud®, Amwell Converge™, Carepoint™ and the Amwell Logo are registered trademarks of American Well Corporation.

Chimerix

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page